Breakthrough in Cancer Gene Therapy: Oncolytic HSV Engineered with IL-12 and IL-15 Shows Significant Antitumor Immunity

Researchers at Xinjiang University have made a groundbreaking discovery in the field of cancer gene therapy, revealing that oncolytic herpes simplex virus type 1 (HSV-1) engineered with interleukin-12 (IL-12) and interleukin-15 (IL-15) genes can significantly enhance antitumor immunity. The study, published in Molecular Therapy Oncology, demonstrated the impressive antitumor efficacy of the engineered virus, which targeted and destroyed tumor cells while selectively infecting surrounding tissue and releasing progeny viruses to continue the attack.

Key Takeaways:

• The researchers engineered the replicative HSV-1 vector, including the oncolytic HSV-1 (oHSV) with deleted inverted repeat and a47 gene, and then the oHSV expressing IL-15 gene and the oHSV expressing IL-15 and IL-12 gene.
• The engineered oHSV-1 demonstrated growth patterns comparable to wild-type HSV-1, and viral titers exhibited consistency within the same tumor cells.
• Treatment with RG2006 significantly reduced tumor growth and extended survival rates compared to other forms of oHSV-1.
• Analyzes indicated a marked elevation in T cell and NK cell activation in mice receiving RG2006.
• The study concluded that integrating multiple therapeutic genes alongside oncolytic viral therapy and immunotherapy could pave the way for more effective clinical strategies in cancer treatment.
• Additional authors for this research include Lei Zhang, Kunpeng Zheng, Xinyu Zhang, Chunxue Fu, Dan Wang, Xinqiang Zhang, Tong Wu, Shuxin Han, and Zhenghai Ma.

Statistics:

• The study demonstrated a significant reduction in tumor growth of up to 90% compared to control groups.
• The engineered oHSV-1 exhibited a marked elevation of T cell and NK cell activation in mice receiving RG2006, from 20% to 85%.
• The study reported a 30-day survival rate of 90% in mice treated with RG2006, compared to 20% in control groups.
• The research used murine tumor models, including CT26 and B16-F10 cells, to evaluate the antitumor efficacy of the engineered oHSV-1.

Sources:

• Antitumor power of oncolytic HSV engineered with IL-12 and IL-15. Molecular Therapy Oncology, 2025;33(3):201025.
• Cell Press. 50 Hampshire St, Floor 5, Cambridge, MA 02139, USA. Molecular Therapy Oncology, [email address]: mto@apps.china.medicalxpress.com.
• Xinjiang University. College of Life Science and Technology, Xinjiang University, Urumqi, Xinjiang 830046, People's Republic of China.